Healthcare
Smith & Nephew plc(SNN)
Live Price
Offline$30.57
-0.33% today
1Y Change
+6.17%
Window
Jun 20, 2025 โ Jun 5, 2026
- Market Cap
- $13.28B
- Revenue Growth
- +6.3%
- EPS Growth
- +55.3%
- Dividend Yield
- 2.5%
Coverage: 241 bars ยท Jun 20, 2025 โ Jun 5, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Smith & Nephew plc (SNN) is a Healthcare stock with a market cap of $13.28B and listed on NYSE. The stock last traded around $30.57 and up 6.2% across the available one-year price window (Jun 20, 2025 โ Jun 5, 2026). Baseline metrics include revenue growth of +6.3%, EPS growth of +55.3%, a dividend yield of 2.5%. What stands out right now is revenue +6.3%, EPS +55.3%, free cash flow +40.9% with operating margin 16.3% and ROIC 9.1%. The dividend matters to the case here, with a current yield around 2.5%. Valuation is more restrained than many high-expectation growth names at P/E 21.2 and price/sales 2.1. Stock Foundry combines SNN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.3% vs +7.6% peer median
Operating Margin
Below sector median
+16.3% vs +19.4% peer median
P/E
Below sector median
21.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on Mar 3, 2026 with an EPS surprise of +1.7% and a revenue surprise of +15.5%.
The operating story is still moving forward
Revenue is running at +6.3% and EPS at +55.3%, with operating margin around 16.3%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 4, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 3, 2026 | +1.7% | -1.1% | -10.0% | -13.5% |
2025 Aug 5, 2025 | -21.7% | +0.1% | +2.1% | +5.3% |
2025 Feb 25, 2025 | -75.5% | +1.2% | +4.8% | +5.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SNN Max Drawdown
-24.81%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SNN and SPY.
Company Overview
Smith & Nephew plc
New York Stock Exchange
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
- Leadership
- Deepak S. Nath
- IPO Date
- Nov 16, 1999
- Employees
- 17.3k
- Street Address
- Building 5
- Mailing
- Watford, WD18 8YE
- Region
- Watford, GB
- Reporting Currency
- USD
- Investor Line
- 44 1923 477 100
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 21.2
- EV/EBITDA
- 10.0
- Price/Sales
- 2.1
- Price/Book
- 2.6
Growth
- Revenue
- +6.3%
- EPS
- +55.3%
- Free Cash Flow
- +40.9%
Profitability
- Gross Margin
- 68.0%
- Operating Margin
- 16.3%
- Net Margin
- 10.1%
- ROE
- 11.8%
- ROIC
- 9.1%
Balance Sheet
- Debt/Equity
- 0.63
- Current Ratio
- 2.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.